G1 Therapeutics IncG1 Therapeutics Inc - ESG Rating & Company Profile powered by AI

Industry Group:Pharmaceuticals

This analysis of G1 Therapeutics Inc was assembled by All Street Sevva using leading machine learning. If you work at G1 Therapeutics Inc and you would like to use your Sustainability rating, please contact us. Complete Sustainability assessment of G1 Therapeutics Inc can be accessed by signing up for free.

G1 Therapeutics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 6.5; made up of an environmental score of 4.8, social score of 6.4 and governance score of 8.0.

SDG Transparency Score for G1 Therapeutics Inc 
Low
0 - 3

6.5

Medium Impact
4 - 6
High
7 - 10
Last Score Update: 2023-07-01
What drives the score for G1 Therapeutics Inc 
4.8

Environmental

6.4

Social

8.0

Governance

Detailed ESG Breakdown
SEVVA Platform offers unique drill down to the underlying sources powering the ratings. Break down your ESG analysis by 17 UN SDGs and 8 additional governance factors.

Peer Group Comparison

RankCompanySDG Transparency Score Performance
1Novartis AG
9.2
High
2Daiichi Sankyo Co Ltd
8.9
High
483Provention Bio Inc
6.6
High
483PuraPharm Corp Ltd
6.6
High
511G1 Therapeutics Inc
6.5
High
511BPH Energy Ltd
6.5
High
511Abcam PLC
6.5
High
.........
2749Xynomic Pharmaceuticals Holdings Inc
0.0
Low
2749Zyden Gentec Ltd
0.0
Low
.........
View the full peer group of 3273 companies on the SEVVA platformSign up for free
Peer Companies Benchmark
SEVVA Platform benchmarks each company against a peer group. View the full score distribution for peers by logging into SEVVA

Frequently Asked Questions

Does G1 Therapeutics Inc have an accelerator or VC vehicle to help deliver innovation?

LockedSign up for free to unlock

Does G1 Therapeutics Inc disclose current and historical energy intensity?

LockedSign up for free to unlock

Does G1 Therapeutics Inc report the average age of the workforce?

LockedSign up for free to unlock

Does G1 Therapeutics Inc reference operational or capital allocation in relation to climate change?

LockedSign up for free to unlock

Does G1 Therapeutics Inc disclose its ethnicity pay gap?

LockedSign up for free to unlock

Does G1 Therapeutics Inc disclose cybersecurity risks?

LockedSign up for free to unlock

Does G1 Therapeutics Inc offer flexible work?

LockedSign up for free to unlock

Does G1 Therapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?

LockedSign up for free to unlock

Does G1 Therapeutics Inc disclose the number of employees in R&D functions?

LockedSign up for free to unlock

Does G1 Therapeutics Inc conduct supply chain audits?

LockedSign up for free to unlock

Does G1 Therapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')

LockedSign up for free to unlock

Does G1 Therapeutics Inc conduct 360 degree staff reviews?

LockedSign up for free to unlock

Does G1 Therapeutics Inc disclose the individual responsible for D&I?

LockedSign up for free to unlock

Does G1 Therapeutics Inc disclose current and historical air emissions?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')

LockedSign up for free to unlock

Is executive remuneration linked to climate performance?

LockedSign up for free to unlock

Does the Board describe its role in the oversight of climate-related risks and opportunities?

LockedSign up for free to unlock

Does G1 Therapeutics Inc disclose current and / or historical scope 2 emissions?

LockedSign up for free to unlock

Does G1 Therapeutics Inc disclose water use targets?

LockedSign up for free to unlock

Does G1 Therapeutics Inc have careers partnerships with academic institutions?

LockedSign up for free to unlock

Did G1 Therapeutics Inc have a product recall in the last two years?

LockedSign up for free to unlock

Does G1 Therapeutics Inc disclose incidents of discrimination?

LockedSign up for free to unlock

Does G1 Therapeutics Inc allow for Work Councils/Collective Agreements to be formed?

LockedSign up for free to unlock

Has G1 Therapeutics Inc issued a profit warning in the past 24 months?

LockedSign up for free to unlock

Does G1 Therapeutics Inc disclose parental leave metrics?

LockedSign up for free to unlock

Does G1 Therapeutics Inc disclose climate scenario or pathway analysis?

LockedSign up for free to unlock

Does G1 Therapeutics Inc disclose current and / or historical scope 1 emissions?

LockedSign up for free to unlock

Are Operating Expesnses linked to emissions reduction?

LockedSign up for free to unlock

Does G1 Therapeutics Inc disclose the pay ratio of women to men?

LockedSign up for free to unlock

Does G1 Therapeutics Inc support suppliers with sustainability related research and development?

LockedSign up for free to unlock

Does G1 Therapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?

LockedSign up for free to unlock

Does G1 Therapeutics Inc reflect climate-related risks in its financial statements?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')

LockedSign up for free to unlock

Is G1 Therapeutics Inc involved in embryonic stem cell research?

LockedSign up for free to unlock

Does G1 Therapeutics Inc disclose GHG and Air Emissions intensity?

LockedSign up for free to unlock

Does G1 Therapeutics Inc disclose its waste policy?

LockedSign up for free to unlock

Does G1 Therapeutics Inc report according to TCFD requirements?

LockedSign up for free to unlock

Does G1 Therapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?

LockedSign up for free to unlock

Does G1 Therapeutics Inc disclose energy use targets?

LockedSign up for free to unlock

Does G1 Therapeutics Inc disclose its Renewable Energy targets?

Only SubscribersSubscription required

Are emissions metrics verified by STBi?

Only SubscribersSubscription required

Does G1 Therapeutics Inc have a policy relating to cyber security?

LockedSign up for free to unlock

Have a different question?

Potential Risks for G1 Therapeutics Inc
These potential risks are based on the size, segment and geographies of the company.

G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, a (CDK) 4/6 inhibitor that is in Phase III clinical trials for patients with first line colorectal cancer; Phase III clinical trial for the treatment of first line triple negative breast cancer; Phase II clinical trial for patients with first line bladder cancer; Phase II clinical trial for patients with combination with the antibody-drug conjugate; and Phase II clinical trial for the treatment of neoadjuvant breast cancer. In addition, the company develops lerociclib, an oral CDK4/6 inhibitor for multiple oncology indications; and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase IIa clinical trials for the treatment of estrogen receptor-positive and HER2-negative breast cancer. The company has a license agreement with EQRx, Inc. and Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat any indication in humans, as well as Nanjing Simcere Dongyuan Pharmaceutical Co., LTD. for the development and commercialization of trilaciclib for any indication in humans through parenteral delivery, and ARC Therapeutics for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.

Sorry!

Failed to process!